95 related articles for article (PubMed ID: 16261166)
1. Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53.
Seo J; Chung YS; Sharma GG; Moon E; Burack WR; Pandita TK; Choi K
Oncogene; 2005 Dec; 24(55):8176-86. PubMed ID: 16261166
[TBL] [Abstract][Full Text] [Related]
2. Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis.
Cheung AM; Hande MP; Jalali F; Tsao MS; Skinnider B; Hirao A; McPherson JP; Karaskova J; Suzuki A; Wakeham A; You-Ten A; Elia A; Squire J; Bristow R; Hakem R; Mak TW
Cancer Res; 2002 Nov; 62(21):6194-204. PubMed ID: 12414647
[TBL] [Abstract][Full Text] [Related]
3. Redundant and differential regulation of multiple licensing factors ensures prevention of re-replication in normal human cells.
Sugimoto N; Yoshida K; Tatsumi Y; Yugawa T; Narisawa-Saito M; Waga S; Kiyono T; Fujita M
J Cell Sci; 2009 Apr; 122(Pt 8):1184-91. PubMed ID: 19339550
[TBL] [Abstract][Full Text] [Related]
4. Functional interplay of p53 and Mus81 in DNA damage responses and cancer.
Pamidi A; Cardoso R; Hakem A; Matysiak-Zablocki E; Poonepalli A; Tamblyn L; Perez-Ordonez B; Hande MP; Sanchez O; Hakem R
Cancer Res; 2007 Sep; 67(18):8527-35. PubMed ID: 17875692
[TBL] [Abstract][Full Text] [Related]
5. Geminin is essential for the development of preimplantation mouse embryos.
Hara K; Nakayama KI; Nakayama K
Genes Cells; 2006 Nov; 11(11):1281-93. PubMed ID: 17054725
[TBL] [Abstract][Full Text] [Related]
6. The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression.
Armata HL; Garlick DS; Sluss HK
Cancer Res; 2007 Dec; 67(24):11696-703. PubMed ID: 18089799
[TBL] [Abstract][Full Text] [Related]
7. T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes.
Fisch P; Boehm T; Lavenir I; Larson T; Arno J; Forster A; Rabbitts TH
Oncogene; 1992 Dec; 7(12):2389-97. PubMed ID: 1461647
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic potential of the DNA replication licensing protein CDT1.
Arentson E; Faloon P; Seo J; Moon E; Studts JM; Fremont DH; Choi K
Oncogene; 2002 Feb; 21(8):1150-8. PubMed ID: 11850834
[TBL] [Abstract][Full Text] [Related]
9. Block of T cell development in P53-deficient mice accelerates development of lymphomas with characteristic RAG-dependent cytogenetic alterations.
Haines BB; Ryu CJ; Chang S; Protopopov A; Luch A; Kang YH; Draganov DD; Fragoso MF; Paik SG; Hong HJ; DePinho RA; Chen J
Cancer Cell; 2006 Feb; 9(2):109-20. PubMed ID: 16473278
[TBL] [Abstract][Full Text] [Related]
10. Gadd45a acts as a modifier locus for lymphoblastic lymphoma.
Hollander MC; Patterson AD; Salvador JM; Anver MR; Hunger SP; Fornace AJ
Leukemia; 2005 May; 19(5):847-50. PubMed ID: 15744335
[TBL] [Abstract][Full Text] [Related]
11. Geminin-Cdt1 balance is critical for genetic stability.
Saxena S; Dutta A
Mutat Res; 2005 Jan; 569(1-2):111-21. PubMed ID: 15603756
[TBL] [Abstract][Full Text] [Related]
12. The Rgr oncogene induces tumorigenesis in transgenic mice.
Jiménez M; Pérez de Castro I; Benet M; García JF; Inghirami G; Pellicer A
Cancer Res; 2004 Sep; 64(17):6041-9. PubMed ID: 15342385
[TBL] [Abstract][Full Text] [Related]
13. Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development.
Dubé N; Bourdeau A; Heinonen KM; Cheng A; Loy AL; Tremblay ML
Cancer Res; 2005 Nov; 65(21):10088-95. PubMed ID: 16267035
[TBL] [Abstract][Full Text] [Related]
14. Loss of histone deacetylase 4 causes segregation defects during mitosis of p53-deficient human tumor cells.
Cadot B; Brunetti M; Coppari S; Fedeli S; de Rinaldis E; Dello Russo C; Gallinari P; De Francesco R; Steinkühler C; Filocamo G
Cancer Res; 2009 Aug; 69(15):6074-82. PubMed ID: 19622775
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms.
Eißmann M; Melzer IM; Fernández SB; Michel G; Hrabě de Angelis M; Hoefler G; Finkenwirth P; Jauch A; Schoell B; Grez M; Schmidt M; Bartholomae CC; Newrzela S; Haetscher N; Rieger MA; Zachskorn C; Mittelbronn M; Zörnig M
Oncogene; 2013 May; 32(20):2586-91. PubMed ID: 22751129
[TBL] [Abstract][Full Text] [Related]
16. Cloning and molecular dissection of the 8.8 kb pig uroplakin II promoter using transgenic mice and RT4 cells.
Kwon DN; Choi YJ; Park JY; Cho SK; Kim MO; Lee HT; Kim JH
J Cell Biochem; 2006 Oct; 99(2):462-77. PubMed ID: 16619260
[TBL] [Abstract][Full Text] [Related]
17. P53-dependent suppression of the human calcyclin gene (S100A6): the role of Sp1 and of NFkappaB.
Króliczak W; Pietrzak M; Puzianowska-Kuznicka M
Acta Biochim Pol; 2008; 55(3):559-70. PubMed ID: 18714402
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
[TBL] [Abstract][Full Text] [Related]
19. Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability.
Pinyol M; Salaverria I; Bea S; Fernández V; Colomo L; Campo E; Jares P
Int J Cancer; 2006 Dec; 119(12):2768-74. PubMed ID: 17036332
[TBL] [Abstract][Full Text] [Related]
20. p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts.
Jackson JG; Pereira-Smith OM
Cancer Res; 2006 Sep; 66(17):8356-60. PubMed ID: 16951143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
